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Background: Patients with critical limb ischemia (CLI) are a heterogeneous population with respect to risk for mortality
and limb loss, complicating clinical decision-making. Endovascular options, compared with bypass, offer a tradeoff
between reduced procedural risk and inferior durability. Risk stratified data predictive of amputation-free survival (AFS)
may improve clinical decision making and allow for better assessment of new technology in the CLI population.
Methods: This was a retrospective analysis of prospectively collected data from patients who underwent infrainguinal vein
bypass surgery for CLI. Two datasets were used: the PREVENT III randomized trial (n  1404) and a multicenter
registry (n 716) from three distinct vascular centers (two academic, one community-based). The PREVENT III cohort
was randomly assigned to a derivation set (n  953) and to a validation set (n  451). The primary endpoint was AFS.
Predictors of AFS identified on univariate screen (inclusion threshold, P< .20) were included in a stepwise selection Cox
model. The resulting five significant predictors were assigned an integer score to stratify patients into three risk groups.
The prediction rule was internally validated in the PREVENT III validation set and externally validated in themulticenter
cohort.
Results: The estimated 1-year AFS in the derivation, internal validation, and external validation sets were 76.3%, 72.5%,
and 77.0%, respectively. In the derivation set, dialysis (hazard ratio [HR] 2.81, P < .0001), tissue loss (HR 2.22,
P .0004), age >75 (HR 1.64, P  .001), hematocrit <30 (HR 1.61, P  .012), and advanced CAD (HR 1.41, P 
.021) were significant predictors for AFS in themultivariable model. An integer score, derived from the ß coefficients, was
used to generate three risk categories (low < 3 [44.4% of cohort], medium 4-7 [46.7% of cohort], high >8 [8.8% of
cohort]). Stratification of the patients, in each dataset, according to risk category yielded three significantly different
Kaplan-Meier estimates for 1-year AFS (86%, 73%, and 45% for low, medium, and high risk groups, respectively). For a
given risk category, the AFS estimate was consistent between the derivation and validation sets.
Conclusion: Among patients selected to undergo surgical bypass for infrainguinal disease, this parsimonious risk
stratification model reliably identified a category of CLI patients with a >50% chance of death or major amputation at 1
year. Calculation of a “PIII risk score” may be useful for surgical decision making and for clinical trial designs in the CLI
population. (J Vasc Surg 2008;48:1464-71.)Critical limb ischemia (CLI), the most advanced form
of peripheral arterial disease (PAD), is associated with a
high risk of cardiovascular events that include major limb
loss, myocardial infarction, stroke, and death.1-4 The esti-
mated rate of all-cause mortality in patients with CLI has
been reported to be as high as 20% within 6 months of
diagnosis and surpasses 50% at 5 years post diagnosis.5,6
These rates exceed those seen in patients with symptom-
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1464atic coronary artery disease (CAD)7,8 and reflect the
global atherosclerotic burden that accompanies a diag-
nosis of CLI.
Open surgical bypass using autogenous vein has tradi-
tionally served as the gold standard limb revascularization
strategy for patients with CLI and infrainguinal disease.
However, over the last decade, the introduction of endo-
vascular treatment methods has begun to challenge this
concept.5,9Much of the impetus driving this paradigm shift
has stemmed from patients and physicians seeking reduced
procedural risk, albeit, with potential trade-offs of inferior
durability and greater cost. As a result, precise risk stratifi-
cation for patients who present with CLI has become
increasingly important in order to improve clinical decision
making and to determine the most appropriate therapy for
individual patients.
This study sought to address this topic by utilizing the
Project of Ex-Vivo graft Engineering via Transfection III
(PREVENT III) database. PREVENT III was a prospec-
tive, randomized, double-blinded, multicenter trial de-
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agent (edifoligide) in preventing autogenous vein graft
failure in 1404 patients who underwent infrainguinal vein
bypass exclusively for the treatment of CLI.10 This trial
incorporated mandated duplex surveillance, independent
adjudication of endpoints by a clinical events committee,
and external contract research organization (CRO) moni-
toring of all study data per industry standards. The objec-
tive of the current investigation was to utilize this unique
database to develop and then validate a precise and easy-to-
use prognostic risk index for amputation free survival (AFS)
in a population of CLI patients selected to undergo surgical
revascularization.
PATIENTS AND METHODS
Data sources
The PREVENT III cohort. Details of the PREVENT
III (PIII) trial design have been described elsewhere11 and
only relevant features are briefly reviewed here. Edifoligide
is a short double-stranded DNA molecule that inhibits cell
cycle gene expression and was hypothesized to reduce
neointimal hyperplasia. However, in the primary PIII anal-
ysis, the treatment of vein grafts with edifoligide was found
to confer no benefit on the prespecified primary and sec-
ondary endpoints.10
The study cohort consisted of 1404 patients with CLI
drawn from 83 community and university hospitals located
across Canada and the United States. All participating
institutions underwent independent review of the study
and received approval from their respective institutional
review boards. Enrollment initiated in November, 2001
and was completed in October, 2003. Detailed character-
istics of the study population may be found in the primary
trial report.10 The inclusion criteria specified patients at
least 18 years of age who underwent infra-inguinal bypass
(IB) with autogenous vein for CLI (defined as gangrene,
nonhealing ischemic ulcer, or ischemic rest pain with he-
modynamic corroboration). Exclusion criteria included
claudication as an indication for IB surgery, or use of a
nonautogenous conduit. Due to the nature of study drug
treatment in PIII (ex vivo application to the vein), in-situ
vein reconstructions were also excluded.
External validation cohort. This cohort was accumu-
lated from three diverse hospitals (two academic—Brigham
and Women’s Hospital and University of South Florida,
one community-based—Sarasota Memorial Hospital) in
the United States. All patients (n  716) in the external
validation cohort had undergone infrainguinal vein bypass
surgery for CLI at one of the three sites, and each subject
had a minimum of 1-year follow-up. Datasets from each of
these three institutions were comprised of consecutive,
nonselected cohorts spanning the inclusive period of 2001
through 2005. Each of these institutions were participating
sites in PIII (contributing a total of 126 patients), and
although practice patterns are not assumed to be uniform
amongst the individual surgeons, all three groups employ
similar approaches including postoperative duplex surveil-lance and prophylactic reintervention to maintain graft
patency, consistent with the PIII study protocol.
Covariates examined. Demographic variables as well
as a detailed vascular exam (including an ankle-brachial
index [ABI] measurement) were collected prior to surgery
as part of a comprehensive history and physical examina-
tion. Age was treated as a dichotomous variable using 75
years of age as the cut-off threshold. Patients were defined
as having advanced coronary artery disease (CAD) based on
documentation of a prior myocardial infarction or surgical
or percutaneous revascularization. Medication usage corre-
sponds to prescription at discharge from the index opera-
tion; in PIII, the decision to prescribe any concomitant
medication before surgery was not protocol-driven and was
left to the discretion of the operating surgeon. Protocol-
specific technical variables related to the surgery were re-
corded at the time of bypass by the operating surgeon.
These variables included, but were not limited to conduit
type and bypass configuration (site of proximal anastomo-
sis, site of distal anastomosis).
Outcomes. The study subjects were followed for 1
year from the time of surgery with postoperative visits at 1,
3, 6, 9, and 12 months post surgery. Outcome events in
PIII were tracked by investigators, and their study staff at
participating centers using specifically designed case report
forms, supported by source documentation. All data were
audited by a CRO before being entered into the trial
database. The primary endpoint, AFS, was a composite
endpoint defined as freedom from ipsilateral amputation
proximal to the ankle and freedom from all-cause mortality.
A total of 44 patients (3.2%) either withdrew or were lost to
follow-up in PREVENT III.
Prediction rule development. Two-thirds (n  953)
of the PREVENT III cohort were randomly assigned to a
derivation set (PIII derivation set) and one-third (n 451)
were assigned to the validation set (PIII validation set). The
baseline demographic and clinical features of the derivation
and validation sets were compared using the t test for
continuous variables and the 2 test for categorical
variables.
A univariate screen to identify potential significant pre-
dictors of AFS was conducted in the PIII derivation set.
Kaplan-Meier survival estimates were determined for each
covariate and Log rank P values were generated to compare
group differences. Cox proportional hazard models were
used to obtain hazard ratios (HR) and 95% confidence
intervals (CI). Associations that yielded a P value  .20 on
univariate screen (as well as gender), were then included in
a multivariable forward stepwise selection model (signifi-
cance criteria 0.25 for entry, 0.05 for removal).
An integer, or whole number, risk score for AFS at 1
year was constructed by assigning weighted points to each
statistically significant independent predictor yielded from
the multivariable analysis. These weighted points were cal-
culated by dividing the ß-coefficient of the predictor by
0.25 and then rounding off to the nearest integer value.
The integer risk score range was then stratified into three
distinct risk categories based on a qualitative assessment of
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value: low risk, medium risk, high risk.
Internal and external validation. The prediction rule
for 1-year AFS was applied to the PIII validation set and the
resulting AFS rates were compared with those obtained
from the PIII derivation set. Subsequently, the prediction
rule was applied to the external multicenter cohort.
All tests were considered statistically significant at an
alpha level of 0.05 (P  .05, two-tailed). All analyses were
performed using SAS version 9.1 (Cary, NC).
RESULTS
The PIII cohort consisted of 1404 patients of whom
953 patients were randomly assigned to the PIII derivation
set and 451 patients were randomly assigned to the PIII
validation set. Baseline patient demographics, medication
usage, comorbid medical conditions, and surgical charac-
teristics were equivalent between the derivation and valida-
tion sets (Table I). The estimated 1-year AFS in the PIII
derivation set was 76.3% and in the PIII validation set was
Table I. Patient characteristics in the PREVENT III
derivation set and the PREVENT III validation set
PIII
derivation set
PIII
validation set
Characteristics n  953 (%) n  451 (%)
Demographics
Female 348 (36.5) 159 (35.3)
Age 75 307 (32.2) 153 (33.9)
African American 173 (18.2) 76 (16.9)
Medications
Statin 431 (45.2) 205 (45.5)
Antiplatelet 759 (79.6) 362 (80.3)
Beta-blocker 554 (58.1) 281 (62.3)
Risk factors
Tissue loss (ulcer or gangrene) 701 (73.6) 345 (76.5)
History of advanced CAD 393 (41.2) 193 (42.8)
Previous ipsilateral bypass 138 (14.5) 58 (12.9)
Smoking (ever) 709 (74.6) 324 (72.0)
Diabetes 610 (64.0) 290 (64.3)
Hypertension 774 (81.2) 372 (82.5)
High cholesterol 445 (46.7) 189 (41.9)
Dialysis-dependent renal failure 105 (11.0) 65 (14.4)
Ankle brachial index 0.3 457 (73.2) 216 (74.5)
Baseline hematocrit 30% 127 (13.5) 57 (12.9)
Baseline lymphocyte 1500
cells/mL3 345 (43.1) 153 (40.1)
Weight 75 kg 502 (53.5) 256 (57.5)
Surgical characteristics
Proximal anastomosis site
CFA 464 (48.7) 223 (49.5)
SFA 234 (24.6) 113 (25.1)
Popliteal 165 (17.3) 75 (16.6)
Distal anastomosis site
Popliteal 320 (34.5) 137 (30.9)
Tibial 505 (54.4) 243 (54.9)
Pedal 103 (11.1) 63 (14.2)
Single segment GSV 781 (82.0) 350 (77.6)
CAD, Coronary artery disease; CFA, common femoral artery; SFA, super-
ficial femoral artery; GSV, greater saphenous vein.72.5%. With regards to the absolute number of events inthe entire PIII cohort, 354 patients either underwentmajor
amputation or died during the 1 year of follow-up; more
specifically, there were 162 amputation events and 228
death events (two events in a single patient were not
counted twice).
Univariate screen. In the univariate analysis (Table
II), all covariates suspected to have a potential effect on the
outcome AFS were tested, given the following two require-
ments: (1) The variable had to be obtainable preoperatively
(in order to be useful for a clinician prior to deciding on a
treatment strategy); and (2) the variable had to have been
collected during the PREVENT III trial. Statistically sig-
nificant predictors of AFS included age greater than or
equal to 75 years (P  .0009), tissue loss at time of
presentation (P  .0001), diabetes (P  .003), history of
tobacco use (P  .0002), history of advanced CAD (P 
.008), CKD class 3 (P .04) and CKD class 4 (P .0001),
dialysis (P  .0001), hematocrit 30% (P  .004), and
lymphocyte count 1500 (P  .0001). As mentioned
above, in order to remain broadly inclusive during covariate
evaluation, any predictor with a univariate P value of  .2
was also included in the multivariable model; these factors
included elevated cholesterol (P  .05), distal anastomosis
to a tibial vessel (P .05), and weight greater than 75 kg
(P  .08).
Independent determinants of AFS and discrimina-
tion into three strata of risk. The multivariable Cox
proportional hazards model identified five statistically sig-
nificant predictors of AFS (Table III): dialysis, tissue loss,
age 75 years, hematocrit 30, and a history of advanced
CAD. According to the magnitude of the HRs, the stron-
gest predictor for death or major amputation within 1 year
of surgery was dialysis-dependency (HR 2.81, CI 1.97-
3.99). Tissue loss as an indication for revascularization was
associated with a HR of 2.22, CI 1.43-3.44. Age75 years
and hematocrit30% each had a greater than 1.5-fold risk
for loss of AFS (HR 1.64, CI 1.21-2.22 and HR 1.61, CI
1.11-2.34, respectively) while a history of advanced CAD
was associated with a HR of 1.41, CI 1.05-1.88.
The integer score assigned to each covariate was used to
calculate each individual patient’s risk score for 1 year AFS.
The scores ranged from 0 to 12 (median 4, interquartile
range 3-5). As shown in Table IV, a clear gradient of
increased risk ranging from 93.1% AFS to 33.0% AFS was
noted to correlate with the magnitude of the risk score.
Based on the Kaplan-Meier estimated AFS rates in the PIII
derivation set, three risk categories were assigned: low risk
(score 3), medium risk (score 4-7), and high risk (score
8). The 1-year AFS rates associated with each risk cate-
gory were significantly different (P value  .0001 for each
comparison): AFS in the low risk group (44.4% of cohort)
was 85.9%, AFS in the medium risk group (46.7% of
cohort) was 73.0%, and AFS in high risk group (8.8% of
cohort) was 44.6% (Table V).
Validation. The integer scoring system derived above
was applied to each patient in the PIII validation set and to
each patient in the external validation set. After stratifica-
tion by risk category, the AFS rate was extremely similar
dney d
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the external validation set (Fig 1). The stratified Kaplan-
Meier curves displayed in Fig 2 demonstrate that all three
cohorts had comparable AFS within each of the three risk
categories.
Composition of each risk group (Fig 3). The entire
PIII cohort was analyzed to determine the breakdown of
patients in each risk group according to each independent
Table II. Univariate amputation-free survival rates and ha
Covariate A
Female Yes
No
Age  75 y Yes
No
African American Yes
No
Statin Yes
No
Beta-blocker Yes
No
Anti-platelet Yes
No
CLI criterion Tissue loss
Rest pain
Diabetes Yes
No
Insulin controlled diabetes Yes
No
Hypertension Yes
No
Elevated cholesterol Yes
No
Smoking (ever) Yes
No
History of advanced CAD Yes
No
CKD class GFR  60 (ref.)
GFR 30-60
GFR 15-30
GFR  15
Dialysis Yes
No
Proximal anastomosis site CFA
SFA
Popliteal
Distal anastomosis site Popliteal
Tibeal
Pedal
Prior ipsilateral bypass Yes
No
ABI (median) 4.2
4.2
ABI 0.3
0.3
SS-GSV Yes
No
Hematocrit 30 Yes
No
Lymphocyte 1500 Yes
No
Weight 75 kg Yes
No
CLI, critical limb ischemia; CAD, coronary artery disease; CKD, chronic kipredictor. High risk classification was assigned to 63% ofthe patients on dialysis, 13% of the patients with tissue loss,
14% of the patients with age75 years, 27% of the patients
with a HCT 30%, and 18% of the patients with CAD.
DISCUSSION
Among patients selected to undergo surgical bypass,
this parsimonious risk stratification model reliably identi-
fied a subgroup of high risk patients who experienced a
ratios in the PREVENT 5III derivation set
tation-free survival HR (95% CI) P value
75.3 1.08 (0.82-1.41) .6
76.7 1.0 (ref)
69.7 1.57 (1.20-2.04) .0009
79.4 1.0 (ref)
73.8 1.19 (0.86-1.64) .304
76.8 1.0 (ref)
77.7 0.86 (0.66-1.21) .27
74.9 1.0 (ref)
76.8 0.93 (0.72-1.22) .61
75.4 1.0 (ref)
76.5 0.93 (0.68-1.28) .66
74.9 1.0 (ref)
72.1 2.50 (1.72-3.66) .0001
87.5 1.0 (ref)
73.2 1.57 (1.17-3.00) .003
81.7 1.0 (ref)
72 1.11 (0.82-1.51) .51
74.6 1.0 (ref)
76 1.08 (0.77-1.52) .21
77.3 1.0 (ref)
73.8 0.78 (0.59-1.00) .05
78.9 1.0 (ref)
79.1 0.59 (0.45-0.78) .0002
67.8 1.0 (ref)
71.9 1.42 (1.10-1.84) .008
79.2 1.0 (ref)
81.7 1.0 (ref)
77.8 1.29 (0.93-1.78) .13
70.5 1.84 (1.03-3.29) .04
54.7 3.03 (2.19-4.20) .0001
49.3 3.09 (2.27-4.20) .0001
79.5 1.0 (ref)
77.4 1.0 (ref)
75.9 1.11 (0.81-1.54) .52
71.9 1.31 (0.92-1.85) .13
80 1.0 (ref)
74 1.36 (1.00-1.83) .05
77.3 1.24 (0.78-1.99) .36
79.4 0.82 (0.55-1.21) .31
75.6 1.0 (ref)
79 1.0 (ref)
74.9 1.22 (0.88-1.69) .24
80.1 1.0 (ref)
75.8 1.24 (0.84-1.83) .28
76 1.0 (ref)
77.1 1.06 (0.75-1.50) .74
66.4 1.65 (1.18-2.31) .004
77.7 1.0 (ref)
69.6 1.75 (1.31-2.33) .0001
81.5 1.0 (ref)
78.5 0.79 (0.61-1.03) .08
73.7 1.0 (ref)
isease; ABI, ankle-brachial index.zard
mpu50% incidence of either death or major amputation
o; CI,
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tissue loss, advanced age, low hematocrit, and advanced
CAD) to calculate the “PIII risk score” can be easily
obtained at the time of initial presentation. We believe that
the PIII risk score (Fig 4) serves as a useful clinical tool for
surgical decision making, enabling physicians to generate a
preprocedure risk estimate that addresses an individual
patient’s likelihood of success or failure after surgical revas-
cularization; future prospective validation studies are nec-
essary to support this claim.
The decision to model AFS as the critical endpoint of
interest was based on our belief that in order to deem a
revascularization procedure a successful and worthwhile
endeavor, at minimum, there should be a reasonable prob-
ability that the patient will remain alive with an intact index
limb at 1 year. If this goal cannot be achieved with a given
Table III. Multivariable model for the prediction of ampu
covariate (PIII derivation set)
Covariates  coefficient
Dialysis 1.03
CLI criterion 0.80
Age  75 y 0.50
Hematocrit 30 0.48
History of advanced CAD 0.34
CLI, critical limb ischemia; CAD, coronary artery disease; HR, hazards rati
Table IV. Estimated 1 year amputation-free survival
stratified according to the calculated risk score (PIII
derivation set)
Risk score Amputation-free survival (%)
1 93.1
2 89.7
3 86.2
4 81.1
5 76.1
6 74.5
7 71.7
8 63
9 51
10 44
11 27.3
12 33
Table V. Estimated one year amputation-free survival and
the associated hazard ratios based on stratification into low,
medium, and high risk groups (PIII derivation set)
Risk
categories
Integer
score
Amputation-free
survival HR (95% CI) P value
Low 3 85.9 1.0 (ref) —
Medium 4-7 73.0 2.11 (1.54-2.89) .0001
High 8 44.6 5.50 (3.73-8.10) .0001
HR, hazards ratio; CI, confidence interval.therapy such as surgical bypass, then alternative therapiesincluding conservative care, endovascular options, or pri-
mary amputation should be strongly considered. The PIII
risk scoremay aid inmaking these, often difficult, treatment
decisions.
The five independent predictors of AFS identified in
this study have all been shown in prior reports to be
associated with survival and/or limb salvage in patients
undergoing infrainguinal revascularization:
● Dialysis-dependent renal failure as a predictor of AFS is
especially relevant given the remarkably high reported
coprevalence of PAD in the end stage renal disease
population which has been estimated at 24%.12 This
factor was clearly the single most dominant determi-
nant of AFS in this cohort of patients with an associ-
ated hazard ratio of 2.81, CI 1.97-3.99. Owens and
colleagues demonstrated a similar pronounced effect
on AFS in a heterogeneous population of patients with
claudication and CLI who underwent first-time surgi-
cal bypass (adjusted hazard ratio in their analysis
3.19).13
● Tissue loss, defined as a nonhealing ulcer or gangrene,
is reported as the primary manifestation in 74% to 82%
of patients with CLI.5,10,14 Previous studies have iden-
tified tissue loss as a significant predictor of amputa-
tion.15,16
● Advanced patient age is a common concern for vascu-
lar physicians as increasing numbers of elderly patients
are presenting with PAD.17 Brosi and colleagues dem-
onstrated a greater than fivefold increase in 1 year mor-
tality when octogenarians were treated with surgical by-
n-free survival with an integer risk score assigned to each
eger score HR (95% CI) P value
4 2.81 (1.97, 3.99) .0001
3 2.22 (1.43, 3.44) .0004
2 1.64 (1.21-2.22) .001
2 1.61 (1.11, 2.34) .012
1 1.41 (1.05, 1.88) .021
confidence interval.
Fig 1. Amputation-free survival at 1 year in the PIII derivation
set, PIII validation set, and external validation set stratified accord-
ing to risk category.tatio
Intpass for CLI as compared with nonoctogenerians.14
ordin
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an independent role in either amputation or death
after bypass surgery. However, prior reports have dem-
onstrated an association between anemia and inci-
sional complications18 as well as with early loss of
bypass graft patency;19 these types of complications
have been demonstrated to ultimately lead to increased
limb loss and mortality in patients with CLI.15 In
addition, anemia has been shown using the National
Veterans Administration Surgical Quality Improve-
ment Program (NSQIP) dataset to confer increased
rates of perioperative infection and mortality in non-
cardiac surgical patients.20
● CAD, either symptomatic or asymptomatic, has been
estimated to be present in greater than 50% of patients
with CLI.21,22 It has been well established that the
large systemic burden of atherosclerotic disease inher-
ent to CLI subjects patients, leads not only to the
immediate risk of morbidity and mortality secondary
to the affected limb, but also to an increased risk of
cardiac death.1,2,4
The absence of diabetes from the final model is deserv-
ing of special comment. In several series of patients with
advanced PAD, patients with diabetes have been noted to
have reduced survival22 and limb salvage.16 Indeed, that
was the case in the univariate analysis of this study. How-
ever, when dialysis and tissue loss were incorporated into
the stepwise regression model, the association between
diabetes and AFS became attenuated and was no longer
significant. Among the population of diabetics analyzed in
Fig 2. Kaplan-Meier curves demonstrating comparabl
validation set, and external validation when stratified acc
Fig 3. Risk category breakdown by predictor (Entire PIII cohort).the entire PIII cohort, the proportion assigned to each ofthe three risk categories was 34%, 54%, and 12% (low risk,
medium risk, and high risk, respectively).
The use of statin therapy is also conspicuously absent
from the final model. In fact, statin use did not demonstrate
an associated with AFS on univariate analysis (P  .27).
This finding may seem at odds with previous publications
linking statins to improved outcomes in patients with pe-
ripheral arterial disease.23-26 However, it is important to
remember that these other studies did not model AFS as
the study endpoint. While statins may have an important
protective role for mortality and major cardiovascular
events (stroke, myocardial infarction), these data did not
putation-free survival in the PIII derivation set, PIII
g to risk category.
Fig 4. Score card.e amdemonstrate an association with AFS.
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stratification for future study designs evaluating new treat-
mentmodalities for CLI. It is our opinion that the results of
novel treatments in low risk patients (44% of this cohort,
estimated AFS 86%) should be held to a high standard with
durability outcomes comparable to those obtained with
surgical bypass. Conversely, in high risk patients (9% of this
cohort), where AFS at 1 year has been shown to be less than
50%, inferior durability may be an acceptable trade-off in
exchange for lower periprocedural risk.
Several limitations inherent to this study design merit
consideration. All patients included in this study underwent
surgical bypass and, by necessity, had to have been deemed
to be acceptable surgical candidates. Furthermore, all of the
patients from whom the prediction rule was derived were
enrolled in a randomized controlled trial. Due to this
upfront selection bias, the PIII risk score may lack general-
izability to all patients presenting with CLI; there is likely to
be a group of greater risk patients who were not available
for evaluation because they were not offered surgical bypass
in the first place. Future prospective validation studies will
be necessary to address this important issue. Therefore, this
risk index should be currently considered only within the
context of patients with CLI that are considered as poten-
tial candidates for an open bypass. We are unable to com-
ment on how this model would perform in patients under-
going endovascular interventions because none of the CLI
patients from whom it was derived or validated underwent
endovascular methods.
Quality of life (QOL) and functional outcomes are of
clear importance and only recently have suchmeasures (and
the use of appropriately validated instruments to assess
them) been incorporated into the analysis of interventions
for CLI.27-29 QOL results have been reported from PIII,30
but were not available from the external datasets. We,
therefore, did not include QOL as an endpoint for model-
ing in this study.
Although all of the data analyzed in this study were
prospectively collected, they were reviewed retrospectively.
As a result, in the design of the present study, we were
limited to those variables that were collected during the
original trial and unable to assess any additional factors that
had not been recorded. Among the notable covariates not
available for analysis were inflammatory markers. Over the
last decade, a wide body of literature has developed point-
ing to the role that inflammation plays in atherosclerosis,31
highlighted by the establishment of C-reactive protein as a
key prognostic indicator.32-34 Unfortunately, we are un-
able to comment on the potential role that inflammatory
markers may play in determining outcomes in patients with
CLI. Similarly, functional/ambulatory status at the time of
presentation is another factor that often weighs heavily into
the decision-making process when evaluating treatment
strategies for patients with CLI; these factors were not
available for this analysis.
Finally, with regards to our methodology, we used
Kaplan-Meier and Cox regression survival analysis in order
to include all patients and to account for any censoring. Asa result, for the purpose of validation,wewere unable to create
receiver operator curves, with an associated c-statistic, as is
often done with logistic regression-based prediction rules.
Validation in this study is therefore subjective (Fig 1) and
does not have an associated P value. Nonetheless, the
different risk strata are clearly comparable between the PIII
derivation set, PIII validation set, and the external valida-
tion set.
CONCLUSIONS
The PIII risk score utilizes five easily obtainable binary
variables—dialysis-dependency, presence of tissue loss, age
75 years, hematocrit 30%, and a history of advanced
CAD—to stratify patients with CLI and surgically correct-
able infrainguinal disease into three distinct categories of
expected amputation-free survival. Prospective evaluation
of this risk score will clarify its utility for clinical decision
making and in clinical trial design.
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